BioTime, Inc.  

(Public, NYSEMKT:BTX)   Watch this stock  
Find more results for NYSEAMEX:BTX
2.19
-0.11 (-4.78%)
After Hours: 2.21 +0.02 (0.87%)
Feb 5, 4:43PM EST  
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.15 - 2.28
52 week 2.15 - 5.95
Open 2.28
Vol / Avg. 300,762.00/288,335.00
Mkt cap 218.26M
P/E     -
Div/yield     -
EPS -0.57
Shares 94.89M
Beta 1.15
Inst. own 36%
Mar 9, 2016
Q4 2015 BioTime Inc Earnings Release (Estimated) Add to calendar
Dec 8, 2015
BioTime Inc at Oppenheimer Healthcare Conference - Webcast
Nov 9, 2015
Q3 2015 BioTime Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -725.98% -834.97%
Operating margin -741.72% -966.63%
EBITD margin - -806.23%
Return on average assets -85.83% -66.02%
Return on average equity -423.12% -152.85%
Employees 117 -
CDP Score - -

Address

1301 Harbor Bay Pkwy
ALAMEDA, CA 94502-2215
United States - Map
+1-510-5213390 (Phone)
+1-510-5213389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioTime, Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines, including tissue banking, cellular therapy, gene therapy and tissue engineering. The Company is engaged to develop cell-based therapeutic products for diseases, such as neurological disorders, cancer, age related macular degeneration, orthopedic disorders, and age-related cardiovascular disease.

Officers and directors

Alfred D Kingsley Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Aditya Mohanty Co-President, Co-Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Michael D. West Ph.D. Co-Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Russell L. Skibsted Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Judith Segall Vice President - Administration, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Stephen L. Cartt Director
Age: 52
Bio & Compensation  - Reuters
Michael H. Mulroy Director
Age: 49
Bio & Compensation  - Reuters
Angus Charles Russell Director
Age: 59
Bio & Compensation  - Reuters
Deborah J. Andrews Independent Director
Age: 57
Bio & Compensation  - Reuters
Neal C. Bradsher Independent Director
Age: 49
Bio & Compensation  - Reuters